Finance

Lists
Why is ZBIO up 3,89%?
Dive Deeper
ZBIO:NASDAQ
Zenas Biopharma Inc
USD 27,26
+3,89%
(+1,02) 1D
USD 26,94
-1,17% (-0,32)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
USD 26,18
High
USD 27,64
Low
USD 26,18
Mkt. cap
1,78 mjd
Avg. vol.
685,10 k
Volume
429,82 k
52-wk high
USD 44,54
52-wk low
USD 13,50
EPS
-USD 8,97
Shares outstanding
65,18 m
No. of employees
167
Open
USD 26,18
High
USD 27,64
Low
USD 26,18
Mkt. cap
1,78 mjd
Avg. vol.
685,10 k
Volume
429,82 k
52-wk high
USD 44,54
52-wk low
USD 13,50
EPS
-USD 8,97
Shares outstanding
65,18 m
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, Massachusetts, Verenigde State van Amerika
Sector-
Websitezenasbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current USD 27,26
USD 55,00 (+101,76%)
Average
USD 44,80 (+64,34%)
Lowest
USD 32,00 (+17,39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
USD 48,00
+76,1%
10/01/2026
Martin Fan
Wedbush
Buy
Maintained
USD 45,00
+65,1%
09/30/2026
Unknown Analyst
Wedbush
Buy
Maintained
USD 45,00
+65,1%
09/30/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
USD 44,00
+61,4%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
USD 32,00
+17,4%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
USD 45,00
+65,1%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
USD 55,00
+101,8%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
USD 44,00
+61,4%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
USD 55,00
+101,8%
03/17/2026
Last report
13 Aug. 2026
Fiscal period
Q2 2026
-USD 1,77 / -USD 0,75
-134,44%miss
Revenue / Est. (USD)
1,00 m / 15,00 m
-93,33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
1,00 m
Cost of goods sold
34,40 m
55,72 m
60,44 m
62,91 m
Cost of revenue
34,40 m
55,72 m
60,44 m
62,91 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,18 m
15,59 m
16,91 m
15,75 m
Operating expense
13,18 m
15,59 m
16,91 m
15,75 m
Total operating expenses
47,58 m
71,31 m
77,35 m
78,66 m
Operating income
-47,58 m
-71,31 m
-77,35 m
-77,66 m
Other non operating income
1,08 m
-7,48 m
-24,00 k
16,00 k
EBT including unusual items
-51,50 m
-240,34 m
-80,99 m
-111,34 m
EBT excluding unusual items
-46,50 m
-73,66 m
-80,99 m
-81,34 m
Income tax expense
-
106,00 k
-
114,00 k
Effective tax rate
-
-0,04%
-
-0,10%
Other operating expenses
-
-
-
-
Net income
-51,50 m
-240,44 m
-80,99 m
-111,46 m
Net profit margin
-
-
-
-11 145,60%
Earnings per share
-1,22
-1,39
-1,46
-1,77
Interest and investment income
-
12,15 m
3,02 m
6,60 m
Interest expense
-
-7,33 m
-6,63 m
-10,30 m
Net interest expenses
-
4,82 m
-3,61 m
-3,70 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,57 m
-71,30 m
-77,34 m
-77,66 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme